Skip to main content
. 2008 Oct 29;105(44):17079–17084. doi: 10.1073/pnas.0806092105

Fig. 5.

Fig. 5.

Combination of AZD2281 with carboplatin and cisplatin prolongs recurrence-free survival and overall survival. (A) Box plots indicate the time after therapy start before tumors relapse back to the size when treatment was initiated. Dosing was as follows: 50 mg of AZD2281 per kg i.p. daily for 28 days (28d) or daily for 100 days (100d), 6 mg of cisplatin per kg i.v. on day 0 (30 min after the first AZD2281 injection), 100 mg of carboplatin per kg i.v. on day 0 (30 min after the first AZD2281 injection). (B) Kaplan–Meyer curves showing the overall survival after 400 days. Wilcoxon signed rank tests: control vs. AZD2281–28d: P < 0.009 (n = 7); control vs. AZD2281–100d: P < 0.009 (n = 7); AZD2281–28d vs. AZD2281–100d: P < 0.009 (n = 7); cisplatin vs. cisplatin+AZD2281–28d: P < 0.019 (n = 9); cisplatin vs. cisplatin+AZD2281–100d: P < 0.014 (n = 7).